Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: interstitial lung disease

PAD4 Antibodies May Help Predict Treatment Response in Rheumatoid Arthritis

Ruth Jessen Hickman, MD  |  January 17, 2020

A study published in Arthritis & Rheumatology highlights how the presence of autoantibodies to peptidylarginine deiminase (PAD) may eventually be used to influence treatment decisions in the management of rheumatoid arthritis (RA), sharpening our understanding of disease subtypes.1 Although follow-up prospective studies are needed, these findings underline some intriguing areas for future investigations in immunobiology….

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:PAD4 autoantibodies

Tashatuvango / shutterstock.com

Myositis-Specific Antibodies Identified

Mithu Maheswaranathan, MD, & Lisa Criscione-Schreiber, MD, MEd  |  January 16, 2020

The idiopathic inflammatory myopathies (IIM) encompass eight categories: 1) dermatomyositis (DM) in adults, 2) juvenile dermatomyositis, 3) amyopathic DM, 4) cancer-associated DM, 5) polymyositis, 6) immune-mediated necrotizing myopathy, 7) inclusion body myositis, and 8) overlap myositis.1 These categories help classify the myopathies based on clinical and histologic features. The incidence of IIM is estimated at…

Filed under:ConditionsMyositis Tagged with:dermatomyositisidiopathic inflammatory myopathiesidiopathic inflammatory myositismyositis-specific antibodiespolymyositis

Off-Label Coverage of Mycophenolate for Scleroderma under Medicare Part D

From the College  |  January 6, 2020

Based on a request by the ACR Insurance Subcommittee, off-label use of mycophenolate for scleroderma has been added to a Medicare-approved compendium.

Filed under:InsurancePractice SupportSystemic Sclerosis Tagged with:ACR Insurance Subcommittee (ISC)Medicare Part DMycophenolateoff-label useScleroderma

FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations

Michael Putman, MD  |  December 18, 2019

The U.S. Food & Drug Admin­istration (FDA) approved nintedanib for systemic sclerosis associated interstitial lung disease (SSc-ILD) on Sept. 6 after a randomized, controlled trial (SENSCIS) demonstrated significant benefit against placebo.1 At a cost of $96,000 per year, treatment reduced the adjusted annual rate of change in forced vital capacity (FVC) from –93.3 mL in…

Filed under:ConditionsDrug UpdatesSystemic Sclerosis Tagged with:interstitial lung disease (ILD)nintedanibSSc-ILDsystemic sclerosis (SSc)

Case Report: Rheumatoid Arthritis-Associated Restrictive Pericarditis

Scott Rodriguez, MD, Kenton Powell, MD, & Daniel Albert, MD  |  November 17, 2019

Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects approximately 1% of the adult population, and involvement of extra-articular tissue occurs in approximately 40% of patients over their lifetimes.1 RA-associated pericardial disease is an uncommon complication, and surgery is the only definitive therapy—according to current literature. In this report, we present the case of…

Filed under:ConditionsRheumatoid Arthritis Tagged with:anti-CD20 therapyPericarditisrituximab

Case Report: Not All Crystals Are Gout

Katherine Yates, MD, Erin H. Penn, MD, & Minna J. Kohler, MD   |  August 16, 2019

Patients with chronic kidney disease (CKD) often experience joint pain due to various etiologies, including crystalline arthropathies, renal osteodystrophy, amyloid arthropathy, erosive osteoarthritis, avascular necrosis and even erosive spondylarthrosis.1 Below, we present a case of crystalline arthropathy in a patient with chronic kidney disease, mistaken for gout. The Case A 29-year-old man was admitted to…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:chronic kidney diseasecrystal arthropathiesGout

New Studies Identify Possible Markers of Early Systemic Sclerosis

Bryn Nelson, PhD  |  August 16, 2019

Although the true cause of systemic sclerosis (SSc), or scleroderma, remains unknown, researchers have made progress in detecting the autoimmune disease’s early presence. Beyond the physiological signs of Raynaud’s phenomenon, a capillaroscopy can detect alterations in microcirculation and lab tests can confirm the presence of telltale autoantibodies, such as anti-topoisomerase 1, anti-centromere and anti-RNA polymerase…

Filed under:ConditionsResearch RheumSystemic Sclerosis Tagged with:inflammatory markersmacrophagesystemic sclerosis (SSc)

The Prevalence, Incidence, Mortality & Costs of RA-Related ILD

Kurt Ullman  |  July 18, 2019

Interstitial lung disease (ILD) can be associated with rheumatoid arthritis (RA) with significant morbidity and mortality. An article in The Journal of Rheumatology focused on calculating the prevalence, incidence, mortality and costs to the healthcare system of RA-related ILD (RA-ILD).1 “RA is the most common of connective tissue diseases encountered by rheuma­tologists—affecting about 1% of…

Filed under:ConditionsRheumatoid Arthritis Tagged with:costsfinanceInterstitial Lung Diseasemorbiditysurvival

Andrey_Popov a/ shutterstock.com

What Attracts Us to Rheumatology? A Veteran Rheumatologist Reflects

Ronald J. Anderson, MD  |  July 18, 2019

What attracts physicians to a career in rheumatology? Traditionally, the foundation of clinical training at both the medical student and house staff level is based on inpatient services. There are many reasons for this, predominantly revolving around access to patients available for teaching. The result: Trainees are predominantly exposed to a group of conditions that…

Filed under:Professional TopicsWorkforce Tagged with:Career

Myositis Autoantibodies as Biomarkers

Lara C. Pullen, PhD  |  June 4, 2019

A recent study details the autoantibodies of patients with myositis, confirming most patients carry these antibodies. The results also describe how myositis-specific autoantibodies can be used to identify distinct clinical subsets of idiopathic inflammatory myopathy…

Filed under:ConditionsMyositis Tagged with:autoantibodiesidiopathic inflammatory myopathiesILDInterstitial Lung Diseasemyositis

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 26
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences